Back to search
FDAFDA · Food and drugs·Recall number D-0926-2017

Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8.

Published July 5, 2017 · Recall initiated: June 12, 2017

Summary

FDA records drug Class III recall D-0926-2017, published July 5, 2017 and initiated June 12, 2017. Recalling firm: Sanofi-Aventis U.S. LLC; Status: Terminated; Reported quantity: 2980 bottles; Lot: Lot #: 5J69A, Exp 02/19; 6GF2A, 6GF3A, Exp 08/19. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Superpotent Drug: high out-of-specification result for magnesium.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sanofi-Aventis U.S. LLC
Distributor
Nationwide in the USA, Puerto Rico, and the United Kingdom.
Lot
Lot #: 5J69A, Exp 02/19; 6GF2A, 6GF3A, Exp 08/19
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Gaviscon (Alumina & Magnesium Trisilicate) Regular Strength Original Flavor Chewable Tablets, 80 mg & 14.2 mg, 100-count bottles, Distributed by: GlaxoSmithKline Consumer Healthcare, L.P., Moon Twp, PA 15108, UPC 3 0088-1175-47 8. recalled?

Yes. FDA published recall D-0926-2017 on July 5, 2017. Reported hazard: Superpotent Drug: high out-of-specification result for magnesium.

What should I do if I have this product?

Voluntary: Firm initiated · Letter